{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:17:16Z","timestamp":1790882236761,"version":"4.1.0"},"reference-count":65,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005310","name":"Claire and Am\u00e9d\u00e9e Maratier Institute for the Study of Blindness and Visual Disorders, Tel Aviv University","doi-asserted-by":"publisher","award":["No Grant Number"],"award-info":[{"award-number":["No Grant Number"]}],"id":[{"id":"10.13039\/501100005310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Choroidal neovascularization (CNV) is a complication of age-related macular degeneration and a major contributing factor to vision loss. In this paper, we show that in a mouse model of laser-induced CNV, systemic administration of Butyroyloxymethyl-diethyl phosphate (AN7), a histone deacetylase inhibitor (HDACi), significantly reduced CNV area and vascular leakage, as measured by choroidal flatmounts and fluorescein angiography. CNV area reduction by systemic AN7 treatment was similar to that achieved by intravitreal bevacizumab treatment. The expression of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF-2), and the endothelial cells marker CD31, was lower in the AN7 treated group in comparison to the control group at the laser lesion site. In vitro, AN7 facilitated retinal pigmented epithelium (RPE) cells tight junctions\u2019 integrity during hypoxia, by protecting the hexagonal pattern of ZO-1 protein in the cell borders, hence reducing RPE permeability. In conclusion, systemic AN7 should be further investigated as a possible effective treatment for CNV.<\/jats:p>","DOI":"10.3390\/ijms20030714","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T11:50:33Z","timestamp":1549540233000},"page":"714","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model"],"prefix":"10.3390","volume":"20","author":[{"given":"Mor","family":"Dahbash","sequence":"first","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Laboratory of Eye Research, Felsenstein Medical Research Center, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruti","family":"Sella","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Department of Ophthalmology, Rabin Medical Center, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Megiddo-Barnir","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rabin Medical Center, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Nisgav","sequence":"additional","affiliation":[{"name":"Laboratory of Eye Research, Felsenstein Medical Research Center, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Tarasenko","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Laboratory of Experimental Pharmacology and Oncology, Felsenstein Medical Research Center, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Weinberger","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Laboratory of Eye Research, Felsenstein Medical Research Center, Petach Tikva 49100, Israel"},{"name":"Department of Ophthalmology, Rabin Medical Center, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Rephaeli","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Laboratory of Experimental Pharmacology and Oncology, Felsenstein Medical Research Center, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Livnat","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Laboratory of Eye Research, Felsenstein Medical Research Center, Petach Tikva 49100, Israel"},{"name":"National Hemophilia Center, Institute of Thrombosis, and the Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0161-6420(86)33609-1","article-title":"Choroidal Neovascularization","volume":"93","author":"Green","year":"1986","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","article-title":"Choroidal neovascularization","volume":"137","author":"Grossniklaus","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fine, S.L. (2000). Age-Related Macular Degeneration. N. Engl. J. Med., 483\u2013492.","DOI":"10.1056\/NEJM200002173420707"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4172\/1948-5956.1000235","article-title":"Regulation of tumor angiogenesis and choroidal neovascularization by endogenous angioinhibitors","volume":"5","author":"Gunda","year":"2013","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.preteyeres.2003.08.001","article-title":"Retinal and choroidal angiogenesis: Pathophysiology and strategies for inhibition","volume":"22","author":"Das","year":"2003","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9394(14)70868-2","article-title":"Factors controlling ocular angiogenesis","volume":"124","author":"Casey","year":"1997","journal-title":"Am. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/excr.2001.5187","article-title":"Histone acetylation and chromatin remodeling","volume":"265","author":"Gregory","year":"2001","journal-title":"Exp. Cell Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.bjc.6601575","article-title":"Linking the epigenetic \u201clanguage\u201d of covalent histone modifications to cancer","volume":"90","author":"Hake","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin Modifications and Their Function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/13543784.13.1.21","article-title":"Histone deacetylase inhibitors in clinical development","volume":"13","author":"Rosato","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone Deacetylase Inhibitors: Overview and Perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1517\/13543784.11.12.1695","article-title":"Histone deacetylase inhibitors: From target to clinical trials","volume":"11","author":"Kelly","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1167\/iovs.12-11529","article-title":"Inhibition of HDAC2 protects the retina from ischemic injury","volume":"54","author":"Fan","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chen, B., and Cepko, C.L. (2007). Requirement of histone deacetylase activity for the expression of critical photoreceptor genes. BMC Dev. Biol., 7.","DOI":"10.1186\/1471-213X-7-78"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1167\/iovs.06-1364","article-title":"Histone deacetylase inhibition-mediated differentiation of RGC-5 cells and interaction with survival","volume":"48","author":"Schwechter","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Anderson, K.W., Chen, J., Wang, M., Mast, N., Pikuleva, I.A., and Turko, I.V. (2015). Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126592"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1167\/iovs.12-10850","article-title":"Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells","volume":"54","author":"Chindasub","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.exer.2014.07.012","article-title":"Acetylation: A lysine modification with neuroprotective effects in ischemic retinal degeneration","volume":"127","author":"Alsarraf","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1167\/iovs.09-3903","article-title":"Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells","volume":"51","author":"Biermann","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2007.06.053","article-title":"Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity","volume":"149","author":"Chen","year":"2007","journal-title":"Neuroscience"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1167\/iovs.09-4538","article-title":"Inhibition of histone deacetylase protects the retina from ischemic injury","volume":"51","author":"Crosson","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chan, N., He, S., Spee, C.K., Ishikawa, K., and Hinton, D.R. (2015). Attenuation of choroidal neovascularization by histone deacetylase inhibitor. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120587"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1021\/mp800178b","article-title":"N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis","volume":"6","author":"Kim","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<379::AID-DDR20>3.0.CO;2-8","article-title":"Nudelman, a Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications","volume":"50","author":"Rephaeli","year":"2000","journal-title":"Drug Dev. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10637-006-6213-1","article-title":"The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs","volume":"24","author":"Rephaeli","year":"2006","journal-title":"Investig. New Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0223-5234(00)01199-5","article-title":"Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases","volume":"36","author":"Nudelman","year":"2001","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10585-008-9179-x","article-title":"Histone deacetylase inhibitors: The anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)","volume":"25","author":"Tarasenko","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/jm049428p","article-title":"The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters","volume":"48","author":"Nudelman","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1089\/jop.2016.0017","article-title":"Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model","volume":"33","author":"Bahar","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/jcm4020343","article-title":"Age-Related Macular Degeneration: Advances in Management and Diagnosis","volume":"4","author":"Yonekawa","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.exer.2010.07.011","article-title":"Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF","volume":"91","author":"Kim","year":"2010","journal-title":"Exp. Eye Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00941723","article-title":"Expression of vascular endothelial growth factor in experimental choroidal neovascularization","volume":"235","author":"Ishibashi","year":"1997","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.arr.2009.06.002","article-title":"Regulatory role of HIF-1\u03b1 in the pathogenesis of age-related macular degeneration (AMD)","volume":"8","author":"Arjamaa","year":"2009","journal-title":"Ageing Res. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","article-title":"Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration","volume":"29","author":"Forooghian","year":"2009","journal-title":"Retina"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ajo.2006.05.061","article-title":"Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular Diseases","volume":"142","author":"Kaiser","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"IVAN study investigators Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ijc.21030","article-title":"In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer","volume":"116","author":"Rephaeli","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/jcb.26512","article-title":"Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors","volume":"119","author":"Tarasenko","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"Prince","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2010.02.010","article-title":"Histone deacetylases and epigenetic therapies of hematological malignancies","volume":"62","author":"Mercurio","year":"2010","journal-title":"Pharmacol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/ajpheart.00156.2016","article-title":"Changes in cardiac Na v 1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors","volume":"311","author":"Xu","year":"2016","journal-title":"Am. J. Physiol.\u2014Hear. Circ. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Suraweera, A., O\u2019Byrne, K.J., and Richard, D.J. (2018). Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00092"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhang, H., Dai, X., Qi, Y., He, Y., Du, W., and Pang, J.J. (2015). Histone deacetylases inhibitors in the treatment of retinal degenerative diseases: Overview and perspectives. J. Ophthalmol.","DOI":"10.1155\/2015\/250812"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.actbio.2018.03.002","article-title":"Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease","volume":"71","author":"Ratay","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1167\/iovs.18-23826","article-title":"Trichostatin A Ameliorates Conjunctival Fibrosis in a Rat Trabeculectomy Model","volume":"59","author":"Sung","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bjo.2009.175356","article-title":"Therapeutic potential of valproic acid for retinitis pigmentosa","volume":"95","author":"Clemson","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): Characterization of the classical HDAC family","volume":"370","author":"Caron","year":"2003","journal-title":"Biochem. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0162596","article-title":"Histone Deacetylase Inhibition Restores Retinal Pigment Epithelium Function in Hyperglycemia","volume":"11","author":"Desjardins","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2007.05.011","article-title":"The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties","volume":"256","author":"Tarasenko","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tarasenko, N., Cutts, S.M., Phillips, D.R., Inbal, A., Nudelman, A., Kessler-Icekson, G., and Rephaeli, A. (2012). Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031393"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10637-010-9542-z","article-title":"The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity","volume":"30","author":"Tarasenko","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-230X(02)86002-X","article-title":"Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation","volume":"86","author":"Lehrmann","year":"2002","journal-title":"Adv. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/med.20024","article-title":"Histone deacetylation in epigenetics: An attractive target for anticancer therapy","volume":"25","author":"Mai","year":"2005","journal-title":"Med. Res. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2174\/138161207781039689","article-title":"Fibroblast growth factors\/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies","volume":"13","author":"Rusnati","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/sj.onc.1204231","article-title":"Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: A comparative study with VEGF","volume":"20","author":"Zubilewicz","year":"2001","journal-title":"Oncogene"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.exer.2005.05.007","article-title":"Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration","volume":"82","author":"Bhutto","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_64","first-page":"3178","article-title":"Growth factor localization in choroidal neovascular membranes of age-related macular degeneration","volume":"35","author":"Amin","year":"1994","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/02713683.2017.1349154","article-title":"Mobile Laser Indirect Ophthalmoscope: For the Induction of Choroidal Neovascularization in a Mouse Model","volume":"42","author":"Weinberger","year":"2017","journal-title":"Curr. Eye Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/714\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:31:33Z","timestamp":1760185893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["ijms20030714"],"URL":"https:\/\/doi.org\/10.3390\/ijms20030714","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]}}}